NASDAQ:DRUG Bright Minds Biosciences (DRUG) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free DRUG Stock Alerts $0.99 -0.06 (-5.71%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.98▼$1.0650-Day Range$0.99▼$1.8652-Week Range$0.93▼$6.44Volume24,369 shsAverage Volume16,249 shsMarket Capitalization$4.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Bright Minds Biosciences alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Bright Minds Biosciences Stock (NASDAQ:DRUG)Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Read More DRUG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRUG Stock News HeadlinesMay 2, 2024 | americanbankingnews.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Large Increase in Short InterestMay 2, 2024 | americanbankingnews.comBright Minds Biosciences (NASDAQ:DRUG) Trading 7.8% Higher May 5, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.January 12, 2024 | msn.comPsyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And MoreDecember 6, 2023 | finance.yahoo.comBright Minds Announces Non-Brokered Private Placement Fully Subscribed by ManagementNovember 12, 2023 | msn.comPsyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & MoreNovember 12, 2023 | finance.yahoo.comBright Minds Biosciences Inc. (DRUG.CN)October 25, 2023 | benzinga.comBright Minds Biosciences Stock (NASDAQ:DRUG) Dividends: History, Yield and DatesMay 5, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.August 18, 2023 | seekingalpha.comDRUG Bright Minds Biosciences Inc.August 8, 2023 | msn.comBright Minds stock rallies ahead of conference call to discuss Phase 1 dataAugust 8, 2023 | finance.yahoo.comBright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101August 7, 2023 | msn.comBright Minds reports results from trial to treat refractory epilepsiesJuly 24, 2023 | benzinga.comCybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical TrialsJuly 20, 2023 | finance.yahoo.comBright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101July 12, 2023 | benzinga.comBright Minds Biosciences Stock (NASDAQ:DRUG), Short Interest ReportJuly 11, 2023 | msn.comBright Minds Goes For 5:1 Shares Consolidation, Hopes To Regain NASDAQ ComplianceJuly 11, 2023 | finanznachrichten.deBright Minds Biosciences: Bright Minds Announces Effective Date of Share ConsolidationJune 22, 2023 | finanznachrichten.deBright Minds Biosciences: Bright Minds Announces Proposed Share ConsolidationJune 22, 2023 | finance.yahoo.comBright Minds Announces Proposed Share ConsolidationMay 16, 2023 | benzinga.comBright Minds Biosciences Stock (NASDAQ:DRUG), Earnings Estimates, EPS, and RevenueApril 20, 2023 | benzinga.comBright Minds Biosciences Stock (NASDAQ:DRUG), Analyst Ratings, Price Targets, PredictionsApril 19, 2023 | benzinga.comBright Minds Biosciences Stock (NASDAQ:DRUG), Trade IdeasApril 19, 2023 | finance.yahoo.comBright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202April 10, 2023 | finance.yahoo.comBright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin ResearchFebruary 27, 2023 | finance.yahoo.comBright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023February 8, 2023 | finance.yahoo.comBright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee RequirementsSee More Headlines Receive DRUG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/12/2024Today5/05/2024Next Earnings (Estimated)5/20/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DRUG CUSIPN/A CIK1827401 Webbrightmindsbio.com Phone64-7407-2515FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-91.83% Return on Assets-83.54% Debt Debt-to-Equity RatioN/A Current Ratio8.01 Quick Ratio8.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book0.76Miscellaneous Outstanding Shares4,430,000Free Float2,542,000Market Cap$4.39 million OptionableNot Optionable Beta1.45 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Ian McDonald (Age 35)Co-Founder, CEO, President & Director Mr. Ryan E. S. K. Cheung B.Com. (Age 46)CA, CPA, Chief Financial Officer Comp: $87.44kDr. Jan Torleif Pedersen M.Sc. (Age 59)Ph.D., Chief Science Officer & Director Comp: $177.46kDr. Mark A. Smith M.D. (Age 69)Ph.D., Chief Medical Officer Comp: $238.66kDr. Emer Leahy M.B.A. (Age 57)Ph.D., Consultant Key CompetitorsArtelo BiosciencesNASDAQ:ARTLExicureNASDAQ:XCURPetros PharmaceuticalsNASDAQ:PTPIEnsysce BiosciencesNASDAQ:ENSCGenprexNASDAQ:GNPXView All CompetitorsInstitutional OwnershipAdvisorShares Investments LLCBought 20,189 shares on 2/14/2024Ownership: 4.246%View All Institutional Transactions DRUG Stock Analysis - Frequently Asked Questions How have DRUG shares performed in 2024? Bright Minds Biosciences' stock was trading at $1.43 on January 1st, 2024. Since then, DRUG stock has decreased by 30.8% and is now trading at $0.99. View the best growth stocks for 2024 here. Are investors shorting Bright Minds Biosciences? Bright Minds Biosciences saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 75,700 shares, an increase of 7.2% from the March 31st total of 70,600 shares. Based on an average daily volume of 24,400 shares, the short-interest ratio is presently 3.1 days. Currently, 2.8% of the company's shares are sold short. View Bright Minds Biosciences' Short Interest. When is Bright Minds Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our DRUG earnings forecast. How were Bright Minds Biosciences' earnings last quarter? Bright Minds Biosciences Inc. (NASDAQ:DRUG) issued its quarterly earnings results on Monday, February, 12th. The company reported ($0.32) EPS for the quarter. When did Bright Minds Biosciences' stock split? Bright Minds Biosciences's stock reverse split on Friday, July 14th 2023. The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Bright Minds Biosciences? Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DRUG) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMysterious Gold Leverage Just AnnouncedStansberry ResearchThe only AI company you should be looking atBehind the MarketsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
